UAE Trends and Developments Contributed by: Winsome Cheung and Haykel Hajjaji, Covington & Burling LLP
historic fragmentation between federal and Emir- ate‑level regulators and to promote a more predict- able, transparent, and globally aligned regulatory environment. For companies, the expanded regulatory landscape means a greater range of activities now fall under for- mal licensing and supervision. Organisations involved in research, manufacturing, marketing, or distribution must adopt a more holistic approach to assessing their regulatory footprint, especially where activities span multiple product categories or involve cross‑bor- der operations. Institutional co-ordination and regulatory practice Although regulatory authority is increasingly central- ised at the federal level, Emirate‑level health authorities continue to play a critical role in licensing healthcare facilities, practitioners, and research sites. Companies must therefore navigate a layered regulatory environ- ment, particularly when conducting clinical trials or operating healthcare facilities in specific Emirates. Co-ordination between federal and local authorities has improved, but differences in administrative pro- cesses and timelines may persist. Early engagement with relevant regulators and a clear understanding of jurisdictional competencies remain essential to man- aging approval pathways and mitigating compliance risks. As the new federal framework is implemented, regu- latory practice continues to evolve. Authorities are developing internal procedures, digital platforms, and guidance materials. Companies should anticipate a period of adjustment as expectations become clearer through practice rather than formal rule-making alone. Market access and approval pathways The updated regulatory framework introduces new market access pathways designed to support inno- vation and timely patient access. These include con- ditional marketing authorisations for orphan and rare disease treatments, emergency use authorisations, and fast‑track procedures for innovative medical products addressing significant therapeutic needs.
These mechanisms aim to shorten approval timelines while maintaining safety and efficacy standards. For innovative companies, the availability of differentiated pathways may influence clinical development strat- egies, launch sequencing, and regional investment decisions. However, the operation of these pathways is closely tied to regulatory discretion and detailed implement- ing guidance. Companies aiming to use acceler- ated or conditional approvals must be prepared for intensive engagement with regulators and must meet post‑authorisation obligations. Pricing and reimbursement dynamics Pricing and reimbursement remain central to market access strategy. Pharmaceutical pricing is subject to regulatory oversight, with authorities seeking to bal- ance affordability, supply security, and incentives for innovation. There are signs of increased openness to value‑based considerations, particularly for innovative therapies targeting serious or rare conditions. Nonetheless, pricing negotiations can be complex, with outcomes influenced by product category, therapeutic area, and anticipated patient population. Reimbursement occurs through government‑funded programmes administered largely at the Emirate lev- el. In 2023, the UAE established a Supreme National Committee for Unified Procurement to introduce a federal procurement programme aimed at achieving financial efficiencies; however, implementing regula- tions are still pending, and mechanisms may evolve. For companies entering the UAE, pricing strategy should be integrated early into regulatory planning, as misalignment between approval and pricing pro- cesses can impact launch timelines and commercial viability. Clinical research and trials environment Clinical research has emerged as a strategic pillar of the UAE’s life sciences ecosystem. Since 2023, fed- eral reforms have created a more coherent nation- al framework for clinical trials, including licensing requirements for sponsors, investigators, and CROs,
381 CHAMBERS.COM
Powered by FlippingBook